6 completed, 3 terminated, 1 available, 1 withdrawn. 7 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 3 | 6 | Completed 4, Terminated 2 |
Follow arimoclomol: new trials by email Literature Review of arimoclomol trials Research Report on arimoclomol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial Arimoclomol - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | ZevraDenmark | 120 | 2019-09-19 | 2023-08-24 |
| Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Arimoclomol - Inclusion Body Myositis | Phase 3 | Terminated | ZevraDenmark | 121 | 2019-05-20 | 2023-09-15 |
| Arimoclomol in Amyotropic Lateral Sclerosis Arimoclomol, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | ZevraDenmark | 245 | 2018-07-31 | 2023-08-24 |
| Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 Arimoclomol, Placebo oral capsule - Gaucher Disease, Type 1, Gaucher Disease, Type 3 | Phase 2 | Terminated | ZevraDenmark | 39 | 2018-06-06 | 2023-01-11 |
| Study of Arimoclomol in Inclusion Body Myositis (IBM) Arimoclomol, Placebo - Inclusion Body Myositis | Phase 2 | Completed | ZevraDenmark | 152 | 2017-08-16 | 2023-05-10 |
| Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C arimoclomol, Placebo - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Completed | ZevraDenmark | 50 | 2016-06-14 | 2024-11-29 |
| Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis Arimoclomol, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | University of Miami | 38 | 2009-01-01 | 2019-01-11 |
| Arimoclomol in Sporadic Inclusion Body Myositis Arimoclomol, Placebo - Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Richard Barohn, MD | 24 | 2008-09-01 | 2017-01-19 |
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS arimoclomol - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | CytRx | 80 | 2005-10-01 | 2012-02-09 |
| A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS Placebo, Arimoclomol - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | CytRx | 2012-02-09 | ||
| Early Access Program With Arimoclomol in US Patients With NPC Arimoclomol - Niemann-Pick Disease, Type C | Available | ZevraDenmark | 2024-08-16 |
Amyotrophic Lateral Sclerosis (5) · Myositis, Inclusion Body (3) · Niemann-Pick Disease, Type C (2) · Gaucher Disease (1) · Lysosomal Storage Diseases (1) · Motor Neuron Disease (1) · Myositis (1) · Neuromuscular Diseases (1)
ZevraDenmark (7) · CytRx (2) · Richard Barohn, MD (1) · University of Miami (1)
United States (10) · United Kingdom (6) · Canada (3) · France (3) · Germany (3) · Italy (3) · Poland (3) · Spain (3) · Belgium (2) · Netherlands (2) · Sweden (2) · Switzerland (2) · Denmark (1) · India (1)
Merit Cudkowicz, MD, MSc (2) · Michael Benatar, MD PhD (2) · Aabha Nagral, MD (1) · Jeremy Shefner, MD (1) · Jeremy Shefner, MD, PhD (1) · Karl-Eugen Mengel (1) · Mazen Dimachkie, MD (1) · Mazen M Dimachkie (1) · Merit Cudkowicz, MD (1) · Michael Benatar, MBChB, DPhil (1) · Michael Hanna (1) · Michael Hanna, MD (1)
PMID 29367439, PMID 34418116, PMID 37739573, PMID 38782015, PMID 38960586